Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database

Aneel Paulus, MD, Mayank Sharma, MBBS, Shumail M. Paulus, MBBS, Richa Menghani, MD, Elisa M. Rodriguez, Ryan D Frank, MS, George Cooper, David Hodge, Vivek Roy, MD, Rafael Fonseca, MD, Asher A. Chanan-Khan, MD, Peter Leif Bergsagel, MD, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 4432.

https://doi.org/10.1182/blood.V128.22.4432.4432

Published: 2016

Journal Articles

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

Caleb K. Stein, MS, Charlotte Pawlyn, MB BChir, Shweta S. Chavan, PhD, Niels Weinhold, PhD, Brian A Walker, PhD, Adam Rosenthal, Ola Landgren, MD, PhD, Peter Leif Bergsagel, MD PhD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 4441.

https://doi.org/10.1182/blood.V128.22.4441.4441

Published: 2016

Journal Articles

Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

Yawara Kawano, MDPhD, Michele Moschetta, MD, Katsutoshi Kokubun, PhD, Pavlo Lukyanchykov, MD, Esilida Sula Karreci, MD, Salomon Manier, MD, Shokichi Tsukamoto, MD PhD, Satoshi Takagi, PhD, Jiantao Shi, Michaela R. Reagan, PhD, Daisy Huynh, BS, MS, Antonio Sacco, BS, David M. Dorfman, MD PhD, Marta Chesi, PhD, Peter Leif Bergsagel, MD PhD, Aldo M Roccaro, MD PhD, Jamil Azzi, MD, Irene M. Ghobrial, MD

Blood (2015) 126 (23): 502.

https://doi.org/10.1182/blood.V126.23.502.502

Published: 2015

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood (2015) 126 (23): 3050.

https://doi.org/10.1182/blood.V126.23.3050.3050

Published: 2015

Journal Articles

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Michele Moschetta, MD, Yuji Mishima, PhD, Yawara Kawano, MD PhD, Yosra Aljawai, MS, Bruno Paiva, PhD, Luis Palomera, MD, Arianna Calcinotto, Unitt L. Christine, BSc, Ilyas Sahin, MD, Antonio Sacco, BS, Siobhan Glavey, MD, Michaela R. Reagan, PhD, Salomon Manier, MD, Peter Leif Bergsagel, MD PhD, Marta Chesi, PhD, Matteo Bellone, MD, Aldo M Roccaro, MD PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 4719.

https://doi.org/10.1182/blood.V124.21.4719.4719

Published: 2014

Journal Articles

Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans

Arianna Calcinotto, Maurilio Ponzoni, Roberto Ria, Matteo Grioni, Elena Cattaneo, Isabella Villa, Maria Teresa Sabrina Bertilaccio, Marta Chesi, PhD, Alessandro Rubinacci, Giovanni Tonon, MDPhD, Peter Leif Bergsagel, MD PhD, Angelo Vacca, MD PhD, Matteo Bellone, MD

Blood (2014) 124 (21): 5678.

https://doi.org/10.1182/blood.V124.21.5678.5678

Published: 2014

Journal Articles

Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies

Nadine Hein, PhD, Sean O'Brien, Ph.D., Denis Drygin, PhD, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit Khot, MD, FRCPath, MBBS, MRCP, Carleen Cullinane, PhD, Matthews Geoff, PhD, Marta Chesi, PhD, Peter Leif Bergsagel, MD, Johannes Zuber, MD, Scott W. Lowe, Ph.D., Ricky W Johnstone, PhD, Rick Pearson, PhD, Grant A. McArthur, MD, PhD, FRACP, MBBS, Ross D Hannan, PhD

Blood (2013) 122 (21): 3941.

https://doi.org/10.1182/blood.V122.21.3941.3941

Published: 2013

Journal Articles

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Shaji K Kumar, MD, Vivek Roy, M.D., Craig Reeder, MD, Betsy R. LaPlant, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Kristina Laumann, Melanie Ann Thompson, Thomas E Witzig, MD, Francis K Buadi, MD, Candido E. Rivera, MD, Joseph R. Mikhael, MD, Peter Leif Bergsagel, MD, Lisa Hwa, RN, CNP, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2013) 122 (21): 1944.

https://doi.org/10.1182/blood.V122.21.1944.1944

Published: 2013

Journal Articles

A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort

Joseph R. Mikhael, MD, Craig B. Reeder, MD, Edward N. Libby, III, MD, Luciano J Costa, MD, PhD, Peter Leif Bergsagel, MD, Francis Buadi, MD, Angela Mayo, PA/NP, Katherine Gano, Cassandra Wolf, Amylou Constance Dueck, PhD, A. Keith Stewart, MBA, MB, CHB

Blood (2013) 122 (21): 3179.

https://doi.org/10.1182/blood.V122.21.3179.3179

Published: 2013

Journal Articles

The Murine Vk*MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma.

Marta Chesi, PhD, Jonathan J Keats, PhD, Esteban Braggio, PhD, Peter Leif Bergsagel, MD

Blood (2009) 114 (22): 1808.

https://doi.org/10.1182/blood.V114.22.1808.1808

Published: 2009

Journal Articles

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

Veerendra Munugalavadla, PhD, Leanne Berry, Changchun Du, BM, BS, Sanjeev Mariathasan, Dion Slaga, Laura Sun, Marta Chesi, Peter Leif Bergsagel, MD, Allen J. Ebens, PhD

Blood (2009) 114 (22): 3788.

https://doi.org/10.1182/blood.V114.22.3788.3788

Published: 2009

Journal Articles

The Vk*MYC Mouse Model of Myeloma Accurately Reflects Clinical Efficacy of Established and Novel Drugs.

Marta Chesi, PhD, Stephen Palmer, Peter Leif Bergsagel, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ, USA

Blood (2009) 114 (22): 1849.

https://doi.org/10.1182/blood.V114.22.1849.1849

Published: 2009

Journal Articles

TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia

Blood (2008) 112 (11): 619.

https://doi.org/10.1182/blood.V112.11.619.619

Published: 2008

Journal Articles

Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP).

Wee-Joo Chng, Gaofeng Huang, Peter Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1673.

https://doi.org/10.1182/blood.V112.11.1673.1673

Published: 2008

Journal Articles

Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.

Wee-Joo Chng, Ian Lee, Victor Jimenez-zepeda, Esteban Braggio, Jonathan Keats, Peter Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1682.

https://doi.org/10.1182/blood.V112.11.1682.1682

Published: 2008

Journal Articles

Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS)

David P. Steensma, MD, FACP, Jessemy D Neiger, MD, Julie C Porcher, MS, J. Jonathan Keats, PhD, Peter Leif Bergsagel, MD, Ryan A Knudson, Rafael Santana-Davila, MD, Rajiv Kumar, MD, Rhett Ketterling, MD

Blood (2008) 112 (11): 2679.

https://doi.org/10.1182/blood.V112.11.2679.2679

Published: 2008

Journal Articles

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Martha Q. Lacy, MD, Suzanne R. Hayman, Morie A. Gertz, Jacob B. Allred, Sumithra J. Mandrekar, Angela Dispenzieri, Stephen R. Zeldenrust, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J Russell, Francis Buadi, Robert A. Kyle, Peter Leif Bergsagel, MD, Rafael Fonseca, MD, Vivek Roy, MD, FACP, Joseph Mikhael, MD, A. Keith Stewart, MBChB, MBA, S. Vincent Rajkumar

Blood (2008) 112 (11): 866.

https://doi.org/10.1182/blood.V112.11.866.866

Published: 2008

Journal Articles

Genetic Origin of Myeloma.

Marta Chesi, Peter Leif Bergsagel, MD, Michael Kuehl, MD

Blood (2008) 112 (11): sci-5.

https://doi.org/10.1182/blood.V112.11.sci-5.sci-5

Published: 2008

Journal Articles

Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.

Zhi Hua Li, MD, Peter Leif Bergsagel, MD, Sue Chow, David Hedley, MD, Suzanne Trudel, MD

Blood (2007) 110 (11): 1505.

https://doi.org/10.1182/blood.V110.11.1505.1505

Published: 2007

NARROW

Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available Mmrf Commpass Study Database

The Mutational and Signaling Landscape of Multiple Myeloma Varies Dependent upon Translocation Cyclin D (TC) Subgroup

Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Angiogenesis Associated with Alterations of the Bone Marrow Microenvironment Predicts Multiple Myeloma Progression to Symptomatic Disease in Mice and Humans

Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

A Phase I/II Trial Of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) In Patients With Newly Diagnosed Multiple Myeloma: Final Results Of MTD Expansion Cohort

The Murine Vk*MYC Myeloma Shares Defining Genetic Lesions with Human Multiple Myeloma.

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

The Vk*MYC Mouse Model of Myeloma Accurately Reflects Clinical Efficacy of Established and Novel Drugs.

TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia

Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP).

Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.

Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS)

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Genetic Origin of Myeloma.

Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only